XKDCT 086
Alternative Names: iPD-1-Claudin18.2-CAR-T; XKDCT-086Latest Information Update: 28 Apr 2026
At a glance
- Originator Shenzhen Celconta Life Science
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for clinical-Phase-Unknown development in Solid-tumours(In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in China (IV, Infusion)
- 01 Mar 2023 Clinical trials in Solid tumours (Late-stage disease, In adults, In the elderly, Second-line therapy or greater) in China (IV) (NCT05952375)
- 13 Jan 2023 Preclinical trials in Solid tumours in China (IV)